Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Dasatinib in patients with Chronic Myelogenous Leukemia.

Statements

Source and description
Sprycel (dasatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
Sprycel (dasatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adult patients with chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.
Sprycel (dasatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
Sprycel (dasatinib) [product monograph]. HC. Health Canada approved dasatinib for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
Sprycel (dasatinib) [product monograph]. HC. Health Canada approved dasatinib for the treatment of adults with Ph+ chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate.